IP Library Granted Patent US 10,570,128
Granted Patent B2
US 10,570,128 · App. 15/313,938 · Granted Feb 25, 2020

Agonists of the apelin receptor and methods of use thereof

Inventors: Anthony B. Pinkerton (La Jolla, CA); Layton H. Smith (La Jolla, CA)
Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
C07D471/04A61K31/4196A61K31/422A61K31/427A61K31/4709A61K31/506A61K31/517A61K31/519C07D409/04C07D409/14C07D413/14C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,570,128
App. No.
15/313,938
Granted
Feb 25, 2020
Kind
B2
Abstract

Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance/diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).

Claims (12)

1. A compound of structural Formula I, or a pharmaceutically acceptable salt, polymorph, solvate, tautomer, or N-oxide thereof:

wherein:

A is selected from the group consisting of:

B is selected from the group consisting of:

C is selected from the group consisting of

Y is S; and

X 1 and X 2 are each N.

2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

3. The compound of claim 1 , wherein B is

4. The compound of claim 1 , wherein B is selected from the group consisting of:

5. A compound that has one of the following structures:

or a pharmaceutically acceptable salt, polymorph, solvate, tautomer, or N-oxide thereof.

Assignments (2)
CHANGE OF NAME Recorded Jul 26, 2019
From: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
To: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Reel/Frame 049881/0174 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2018
From: PINKERTON, ANTHONY B.; SMITH, LAYTON H.
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 047086/0732 →
Continuity (2)
Provisional Application 62004195 · May 28, 2014
Related Publication 20170197958A1 · Jul 13, 2017
Cited By (1)
US 12,319,684